ArticleBMC cancer2018
A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Differentially Expressed Genes Identify FIGO Stage II Cervical Cancer Patients with a Higher Risk of Relapse in a Small Cohort.Journal of personalized medicine · 2025Article
- Prognostic signature of endoplasmic reticulum stress-related long noncoding RNAs in head and neck squamous cell carcinoma: Association with somatic mutation and tumor immune microenvironment.Journal of dental sciences · 2023Article
- Identification of novel key genes associated with uterine corpus endometrial carcinoma progression and prognosis.Annals of translational medicine · 2023Article
- DSCAM-AS1 Long Non-Coding RNA Exerts Oncogenic Functions in Endometrial Adenocarcinoma via Activation of a Tumor-Promoting Transcriptome Profile.Biomedicines · 2022Article
- A comprehensive prognostic and immune analysis of enhancer RNA identifies IGFBP7-AS1 as a novel prognostic biomarker in Uterine Corpus Endometrial Carcinoma.Biological procedures online · 2022Article
- The Expression of Pyroptosis-Related Gene May Influence the Occurrence, Development, and Prognosis of Uterine Corpus Endometrial Carcinoma.Frontiers in oncology · 2022Article
- Integrative Analysis Reveals a Nine TP53 Pathway-Related lncRNA Prognostic Signature in Endometrial Cancer.BioMed research international · 2022Article
- COVID-19-associated lncRNAs as predictors of survival in uterine corpus endometrial carcinoma: A prognostic model.Frontiers in genetics · 2022Article
- N1-Methyladenosine-Related lncRNAs Are Potential Biomarkers for Predicting Prognosis and Immune Response in Uterine Corpus Endometrial Carcinoma.Oxidative medicine and cellular longevity · 2022Article
- Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer.Frontiers in oncology · 2022Article
- Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma.Journal of clinical laboratory analysis · 2021Article
- Development of a seven-gene tumor immune microenvironment prognostic signature for high-risk grade III endometrial cancer.Molecular therapy oncolytics · 2021Article
- Construction of a 5 immune-related lncRNA-based prognostic model of NSCLC via bioinformatics.Medicine · 2021Article
- Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune-related lncRNA.Cancer medicine · 2021Article
- Bioinformatic profiling identifies prognosis-related genes in the immune microenvironment of endometrial carcinoma.Scientific reports · 2021Article
- Non-Coding RNAs as Prognostic Markers for Endometrial Cancer.International journal of molecular sciences · 2021Review
- A 4-gene signature predicts prognosis of uterine serous carcinoma.BMC cancer · 2021Article
- Identification and validation of tumor microenvironment-related lncRNA prognostic signature for uveal melanoma.International journal of ophthalmology · 2021Article
- Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.Frontiers in immunology · 2021Article
- The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients' Diagnosis and Prognosis.Brain sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial cancer (UCEC) is a complex malignant tumor characterized by both genetic level and clinical trial. Patients with UCEC exhibit the similar clinical features, however, they have distinct outcomes due to molecular heterogeneity. The aim of this study was to access the prognostic value of long non-coding RNAs (lncRNAs) in UCEC patients and to identify potential lncRNA signature for predicting patients' survival and improving patient-tailored treatment.
methodsWe performed a comprehensive genome-wide analysis of lncRNA expression profiles and clinical data in a large cohort of 301 UCEC patients. UCEC patients were randomly divided into the discovery cohort (n = 150) and validation cohort (n = 151). A novel lncRNA-focus expression signature was identified in the discovery cohort, and independently accessed in the validation cohort. Additionally, the lncRNA signature was evaluated by multivariable Cox regression and stratification analysis as well as functional enrichment analysis.
resultsWe detected a novel lncRNA-focus expression signature (LFES) consisting of 11 lncRNAs that were associated with survival based on risk scoring strategy in UCEC. The risk score based on the LFES was able to separate patients of discovery cohort into high-risk and low-risk groups with significantly different overall survival and progression-free survival, and has been successfully confirmed in the validation cohort. Furthermore, the LFES is an independent prognostic predictor of survival and demonstrates superior prognostic performance compared with the clinical covariates for predicting 5-year survival (AUC = 0.887). Functional analysis has linked the expression of prognostic lncRNAs to well-known tumor suppressor or ontogenetic pathways in endometrial carcinogenesis.
conclusionsOur study revealed a novel 11-lncRNA signature to predict survival of UCEC patient. This lncRNA signature may be a valuable and alternative marker for risk evaluation to aid patient-tailored treatment and improve the outcome of patients with UCEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.